{"id":59900,"date":"2024-09-26T12:05:37","date_gmt":"2024-09-26T12:05:37","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/09\/26\/repair-biotechnologies-and-genevant-sciences-to-collaborate-to-develop-mrna-lnp-therapy-with-first-in-class-potential-to-turn-back-atherosclerosis\/"},"modified":"2024-09-26T12:05:37","modified_gmt":"2024-09-26T12:05:37","slug":"repair-biotechnologies-and-genevant-sciences-to-collaborate-to-develop-mrna-lnp-therapy-with-first-in-class-potential-to-turn-back-atherosclerosis","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/repair-biotechnologies-and-genevant-sciences-to-collaborate-to-develop-mrna-lnp-therapy-with-first-in-class-potential-to-turn-back-atherosclerosis\/","title":{"rendered":"Repair Biotechnologies and Genevant Sciences to Collaborate to Develop mRNA-LNP Therapy with First-in-Class Potential to Turn Back Atherosclerosis"},"content":{"rendered":"<div>\n<p align=\"left\">SYRACUSE, New York, VANCOUVER, British Columbia, and BASEL, Switzerland, Sept.  26, 2024  (GLOBE NEWSWIRE) &#8212; Repair Biotechnologies, a biotechnology company developing first-in-class therapies capable of rapidly regressing atherosclerotic plaque, and Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust and expansive lipid nanoparticle (LNP) patent portfolio, today announced they have entered into a collaboration and nonexclusive license agreement to combine Repair\u2019s Cholesterol Degrading Platform (CDP) mRNA technology with Genevant\u2019s proprietary LNP technology in the development of a potential novel treatment for atherosclerosis.<\/p>\n<p align=\"left\">\u201cOur Cholesterol Degrading Platform enables us to produce therapies designed to reverse the progression of conditions such as atherosclerosis that are driven by localized accumulations of excess cholesterol in the body. Our first CDP mRNA therapy targets atherosclerosis and, as with all mRNA-based approaches, delivery is essential to achieving therapeutic benefit. We are excited to be working with Genevant, a recognized leader in the LNP space,\u201d said Reason, Chief Executive Officer and co-founder of Repair.<\/p>\n<p align=\"left\">\u201cSuccessful development of mRNA and other nucleic acid-based therapies simply cannot happen without efficient delivery, and, with our longstanding leadership position in LNP technology, Genevant is well positioned to help innovative payload companies like Repair accomplish their objectives,\u201d said James Heyes, Chief Scientific Officer of Genevant Sciences. \u201cWe are delighted to collaborate with Repair in the development of a potential new therapeutic option for atherosclerosis.\u201d<\/p>\n<p align=\"left\">Under the terms of the agreement, Genevant has granted to Repair a nonexclusive worldwide license to certain Genevant LNP technology to exploit CDP mRNA-LNP products for a specified field that includes atherosclerosis. Genevant is eligible to receive up to $107 million in upfront and contingent milestone payments per product and tiered royalties ranging from the mid to high single digits on future product sales.<\/p>\n<p align=\"justify\"><strong>About Repair Biotechnologies<\/strong><br \/>Repair Biotechnologies is a preclinical biotechnology company focused on developing drugs for cholesterol and aging-related diseases. The company\u2019s Cholesterol Degrading Platform (CDP) gives rise to first-in-class therapies aimed at reversing atherosclerosis, familial hypercholesterolemia, and other conditions in which excess or modified cholesterol drives pathology. Current therapies such as statins and PCKS9 inhibitors can successfully reduce serum LDL-cholesterol, but are not effective at regressing established atherosclerotic plaque. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=g4dfyBEs0vDIe42oJy8plgQQAQ8yy-iNCx5Kq38lK9ktcebFiGErNIn1hqGTBUUshnLdfGZoy2IjuB8H2Bo1lXY8IW20otN8LA7INj7ZVpgtc-BnNDVxJZVXNq9z7j7V\" rel=\"nofollow noopener\" target=\"_blank\" title=\"www.repairbiotechnologies.com\">www.repairbiotechnologies.com<\/a>.<\/p>\n<p align=\"justify\"><strong>About Genevant Sciences<\/strong><br \/>Genevant Sciences is a leading nucleic acid delivery company with world-class platforms, a robust and expansive lipid nanoparticle (LNP) patent portfolio, and decades of experience and expertise in nucleic acid drug delivery and development. The Company\u2019s scientists have pioneered LNP delivery of nucleic acids for over 20 years, and the Company\u2019s LNP platform, which has been studied across more than a dozen discrete product candidates and is the delivery technology behind the first and only approved systemic RNA-LNP product (patisiran), enables a wide array of RNA-based applications, including vaccines, therapeutic protein production, and gene editing. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IhDh4Q6HyyHGY8khyZimhydEzqkegh8gcdGz_eDfT0WWeONOtw7E3k0KpkVZgzWs-uaE4FwF0zWZlX_m5yMNmA==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"www.genevant.com\">www.genevant.com<\/a>.<\/p>\n<pre>CONTACT: Contact\r\nPete Zorn\r\npete.zorn@genevant.com<\/pre>\n<p><img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/Nzk2YzIwOWYtZTgzMy00ZWZjLWJkYmUtYTc0Nzg1OTAyMmIwLTUwMDExOTMyNw==\/tiny\/Genevant-Sciences.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SYRACUSE, New York, VANCOUVER, British Columbia, and BASEL, Switzerland, Sept. 26, 2024 (GLOBE NEWSWIRE) &#8212; Repair Biotechnologies, a biotechnology company developing first-in-class therapies capable of rapidly regressing atherosclerotic plaque, and Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust and expansive lipid nanoparticle (LNP) patent portfolio, today announced they have [&#8230;]\n","protected":false},"author":1,"featured_media":59901,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-59900","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Repair Biotechnologies and Genevant Sciences to Collaborate to Develop mRNA-LNP Therapy with First-in-Class Potential to Turn Back Atherosclerosis - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/repair-biotechnologies-and-genevant-sciences-to-collaborate-to-develop-mrna-lnp-therapy-with-first-in-class-potential-to-turn-back-atherosclerosis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Repair Biotechnologies and Genevant Sciences to Collaborate to Develop mRNA-LNP Therapy with First-in-Class Potential to Turn Back Atherosclerosis\" \/>\n<meta property=\"og:description\" content=\"SYRACUSE, New York, VANCOUVER, British Columbia, and BASEL, Switzerland, Sept. 26, 2024 (GLOBE NEWSWIRE) &#8212; Repair Biotechnologies, a biotechnolo\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/repair-biotechnologies-and-genevant-sciences-to-collaborate-to-develop-mrna-lnp-therapy-with-first-in-class-potential-to-turn-back-atherosclerosis\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2024-09-26T12:05:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/09\/Genevant-Sciences.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/repair-biotechnologies-and-genevant-sciences-to-collaborate-to-develop-mrna-lnp-therapy-with-first-in-class-potential-to-turn-back-atherosclerosis\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/repair-biotechnologies-and-genevant-sciences-to-collaborate-to-develop-mrna-lnp-therapy-with-first-in-class-potential-to-turn-back-atherosclerosis\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Repair Biotechnologies and Genevant Sciences to Collaborate to Develop mRNA-LNP Therapy with First-in-Class Potential to Turn Back Atherosclerosis\",\"datePublished\":\"2024-09-26T12:05:37+00:00\",\"dateModified\":\"2024-09-26T12:05:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/repair-biotechnologies-and-genevant-sciences-to-collaborate-to-develop-mrna-lnp-therapy-with-first-in-class-potential-to-turn-back-atherosclerosis\/\"},\"wordCount\":493,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/repair-biotechnologies-and-genevant-sciences-to-collaborate-to-develop-mrna-lnp-therapy-with-first-in-class-potential-to-turn-back-atherosclerosis\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/repair-biotechnologies-and-genevant-sciences-to-collaborate-to-develop-mrna-lnp-therapy-with-first-in-class-potential-to-turn-back-atherosclerosis\/\",\"name\":\"Repair Biotechnologies and Genevant Sciences to Collaborate to Develop mRNA-LNP Therapy with First-in-Class Potential to Turn Back Atherosclerosis - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2024-09-26T12:05:37+00:00\",\"dateModified\":\"2024-09-26T12:05:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/repair-biotechnologies-and-genevant-sciences-to-collaborate-to-develop-mrna-lnp-therapy-with-first-in-class-potential-to-turn-back-atherosclerosis\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/repair-biotechnologies-and-genevant-sciences-to-collaborate-to-develop-mrna-lnp-therapy-with-first-in-class-potential-to-turn-back-atherosclerosis\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/repair-biotechnologies-and-genevant-sciences-to-collaborate-to-develop-mrna-lnp-therapy-with-first-in-class-potential-to-turn-back-atherosclerosis\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Repair Biotechnologies and Genevant Sciences to Collaborate to Develop mRNA-LNP Therapy with First-in-Class Potential to Turn Back Atherosclerosis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Repair Biotechnologies and Genevant Sciences to Collaborate to Develop mRNA-LNP Therapy with First-in-Class Potential to Turn Back Atherosclerosis - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/repair-biotechnologies-and-genevant-sciences-to-collaborate-to-develop-mrna-lnp-therapy-with-first-in-class-potential-to-turn-back-atherosclerosis\/","og_locale":"en_US","og_type":"article","og_title":"Repair Biotechnologies and Genevant Sciences to Collaborate to Develop mRNA-LNP Therapy with First-in-Class Potential to Turn Back Atherosclerosis","og_description":"SYRACUSE, New York, VANCOUVER, British Columbia, and BASEL, Switzerland, Sept. 26, 2024 (GLOBE NEWSWIRE) &#8212; Repair Biotechnologies, a biotechnolo","og_url":"https:\/\/english.saigonbiz.com\/vn\/repair-biotechnologies-and-genevant-sciences-to-collaborate-to-develop-mrna-lnp-therapy-with-first-in-class-potential-to-turn-back-atherosclerosis\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2024-09-26T12:05:37+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/09\/Genevant-Sciences.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/repair-biotechnologies-and-genevant-sciences-to-collaborate-to-develop-mrna-lnp-therapy-with-first-in-class-potential-to-turn-back-atherosclerosis\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/repair-biotechnologies-and-genevant-sciences-to-collaborate-to-develop-mrna-lnp-therapy-with-first-in-class-potential-to-turn-back-atherosclerosis\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Repair Biotechnologies and Genevant Sciences to Collaborate to Develop mRNA-LNP Therapy with First-in-Class Potential to Turn Back Atherosclerosis","datePublished":"2024-09-26T12:05:37+00:00","dateModified":"2024-09-26T12:05:37+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/repair-biotechnologies-and-genevant-sciences-to-collaborate-to-develop-mrna-lnp-therapy-with-first-in-class-potential-to-turn-back-atherosclerosis\/"},"wordCount":493,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/repair-biotechnologies-and-genevant-sciences-to-collaborate-to-develop-mrna-lnp-therapy-with-first-in-class-potential-to-turn-back-atherosclerosis\/","url":"https:\/\/english.saigonbiz.com\/vn\/repair-biotechnologies-and-genevant-sciences-to-collaborate-to-develop-mrna-lnp-therapy-with-first-in-class-potential-to-turn-back-atherosclerosis\/","name":"Repair Biotechnologies and Genevant Sciences to Collaborate to Develop mRNA-LNP Therapy with First-in-Class Potential to Turn Back Atherosclerosis - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2024-09-26T12:05:37+00:00","dateModified":"2024-09-26T12:05:37+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/repair-biotechnologies-and-genevant-sciences-to-collaborate-to-develop-mrna-lnp-therapy-with-first-in-class-potential-to-turn-back-atherosclerosis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/repair-biotechnologies-and-genevant-sciences-to-collaborate-to-develop-mrna-lnp-therapy-with-first-in-class-potential-to-turn-back-atherosclerosis\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/repair-biotechnologies-and-genevant-sciences-to-collaborate-to-develop-mrna-lnp-therapy-with-first-in-class-potential-to-turn-back-atherosclerosis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Repair Biotechnologies and Genevant Sciences to Collaborate to Develop mRNA-LNP Therapy with First-in-Class Potential to Turn Back Atherosclerosis"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/59900","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=59900"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/59900\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/59901"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=59900"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=59900"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=59900"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}